GLSI
Greenwich Lifesciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$338.04M
P/E Ratio
—
EPS
$-1.61
Beta
1.38
52W High
$34.10
52W Low
$7.78
50-Day MA
$24.73
200-Day MA
$18.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 / neu-expressing cancers. The company is headquartered in Stafford, Texas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-22.40M |
| Operating Margin | 0.00% |
| Return on Equity | -677.00% |
| Return on Assets | -211.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.36 |
| Price-to-Book | 67.01 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -21.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $14.68M |
| Float | $7.39M |
| % Insiders | 47.86% |
| % Institutions | 12.42% |
Historical Volatility
HV 10-Day
108.19%
HV 20-Day
90.35%
HV 30-Day
80.85%
HV 60-Day
87.92%
HV Rank
56.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($47.50 target)
2
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026